Australian semiconductor company Archer Materials (ASX: AXE) is poised for a groundbreaking 2024 marked by significant technological advancements in its quantum chip and the imminent production of its biochip sensors through collaborative manufacturing efforts with foundry partners worldwide.
Archer has achieved a major milestone through the successful validation of its Biochip graphene field effect transistor (gFET) designs in partnership with German and Dutch foundries. Following this breakthrough, the company has sent its latest Biochip iteration to a semiconductor foundry in Spain, a strategic move that brings it closer to the creation of the first prototypes of its kind.
The decision to engage a Spanish foundry for the new Biochip design not only allows Archer to leverage specialized expertise and cutting-edge facilities but also underscores the foundry's ISO 13485 certification, opening the door to potential future medical manufacturing partnerships. This aligns with Archer's overarching Biochip development strategy that aims to revolutionize medical testing.
Archer's lab-on-a-chip Biochip technology is designed to enable the concurrent testing for disease-related analytes in multiple liquid samples on a single microchip. This breakthrough technology promises to be cost-effective, efficient, and timely, particularly in light of the global healthcare disparities highlighted by the World Health Organisation (WHO) in 2023, emphasizing the urgent need for more accessible universal health services.
Archer's Biochip technology, which integrates graphene with lab-on-a-chip platforms, holds the potential to revolutionize medical testing by enabling the miniaturization and integration of various lab functions on a single chip, facilitating the processing, detection, and analysis of biological samples.
In addition to its pioneering work in biochip technology, Archer has been at the forefront of next-generation technology development, including the creation of a quantum chip for use in mobile devices. The company has secured patents protecting this revolutionary technology across Asia, Europe, and the US. Notably, Archer's recent strides in Biochip manufacturing have garnered attention from investors and industry experts, signaling its commitment to commercializing its innovative technologies.
Archer's global positioning is further strengthened by its strategic collaboration with the World Economic Forum, where it has become the first Australian company to partner with the Forum's Centre for the Fourth Industrial Revolution (C4IR). This partnership, along with Archer's existing alliances with top-tier manufacturers and research hubs, bolsters its ability to secure future manufacturing capabilities and drive technological advancements.
Archer is focused on advancing its quantum processor and Biochip technologies while fostering partnerships that can facilitate the global proliferation of its innovations. With its strong technological capabilities, Archer is well-positioned to achieve these ambitious goals in the near future.
